Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia

References

• Howard DH, Scott RD 2nd. The economic burden of drug resistance. Clin infect Dis. 2005;41(Suppl 4):S283–6.
   PubMedGoogle Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
   PubMed Web of Science ®Google Scholar
• Murugaiyan J, Kumar PA, Rao GS, et al. Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics (Basel). 2022 Feb 4;11(2):200.
   Web of Science ®Google Scholar
• Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2022;27(1):58–72.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174(3):216–229.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Vellucci L, Barone A, et al. Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacol Ther. 2022;236:108236.
   PubMedGoogle Scholar
• de Leon J, Ruan CJ, Schoretsanitis G, et al. A Rational Use of Clozapine Based on Adverse Drug Reactions. Pharmacokinetics, and Clinical Pharmacopsychology. Psychotherapy and psychosomatics. 2020; 89(4) 200–214.
   Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Ucok A, Yağcıoğlu EA, Yıldız M, et al. Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. Psychiatry Res. 2019;275:149–154.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Remington G, Mulsant BH, et al., Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res. 2011;133(1–3): 54–62.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Kane JM, Correll CU, et al., The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6(1): 1.
   PubMed Web of Science ®Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry Revue Canadienne de Psychiatrie. 2017;62(11):772–777.
   PubMed Web of Science ®Google Scholar
• Kane JM, Agid O, Baldwin ML, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019;80(2). DOI:10.4088/JCP.18com12123.
   Web of Science ®Google Scholar
• Kinon BJ; The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS). Front Psychiatry. 2018;9:757.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacol. 2019;44(6):1036–1042.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981–1989.
   PubMed Web of Science ®Google Scholar
• Lally J, Ajnakina O, Di Forti M, et al., Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15): 3231–3240. .
   PubMed Web of Science ®Google Scholar
• Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom. 2017;86(4):189–219.
   PubMed Web of Science ®Google Scholar
• Fallon P, Dursun S, Deakin B. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012;2(1):13–22.
   PubMedGoogle Scholar
• Gillespie AL, Samanaite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17(1):12.
   PubMedGoogle Scholar
• Matrone M, Kotzalidis GD, Romano A, et al. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. Prog Neuro Psychopharmacol Biol Psychiatry. 2022;114:110493.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11–3.
   PubMed Web of Science ®Google Scholar
• Molina V, Sanz J, Sarramea F, et al. Marked hypofrontality in clozapine-responsive patients. Pharmacopsychiatry. 2007;40(4):157–162.
   PubMed Web of Science ®Google Scholar
• Horne CM, Vanes LD, Verneuil T, et al. Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia. NeuroImage Clin. 2021;30:102631.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Manchia M, Marmo F, et al. Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia. Front Psychiatry. 2020;11:369.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203–1210.
   PubMed Web of Science ®Google Scholar
• Kim E, Howes OD, Veronese M, et al. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [(18)F]DOPA PET Study. Neuropsychopharmacol. 2017;42(4):941–950.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio E, Jauhar S, Kim S, et al. The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal (18)F-DOPA PET and voxel-based morphometry study. Mol Psychiatry. 2021;26(4):1332–1345.
   PubMed Web of Science ®Google Scholar
• Jauhar S, Nour MM, Veronese M, et al. A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA psychiatry. 2017;74(12):1206–1213.
   PubMed Web of Science ®Google Scholar
• Mouchlianitis E, Bloomfield MA, Law V, et al., Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42(3):744–752. .
   PubMed Web of Science ®Google Scholar
• Tarumi R, Tsugawa S, Noda Y, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacol. 2020;45(4):632–640.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Nakajima S, Plitman E, et al. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry. 2019;85(7):596–605.
   PubMed Web of Science ®Google Scholar
• Nakahara T, Tsugawa S, Noda Y, et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies. Mol Psychiatry. 2022;27(1):744–757.
   PubMed Web of Science ®Google Scholar
• Sell GL, Barrow SL, Kimberley McAllister A, Chapter 1 - Molecular composition of developing glutamatergic synapses, editors: Rubenstein J, Rakic P, Chen B, Kwan KY, Cline HT Cardin J, Synapse Development and Maturation, Academic Press, 2020, pp. 3–32.
   Google Scholar
• de Bartolomeis A, Avagliano C, Vellucci L, et al. Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. Neurosci Biobehav Rev. 2019;107:795–827.
   PubMed Web of Science ®Google Scholar
• Matas E, John Francis William D, Toro CT. Abnormal expression of post-synaptic proteins in prefrontal cortex of patients with schizophrenia. Neurosci Lett. 2021;745:135629.
   PubMed Web of Science ®Google Scholar
• Rubio JM, Schoretsanitis G, John M, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7(9):749–761.
   PubMed Web of Science ®Google Scholar
• Leucht S, Winter-van Rossum I, Heres S, et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015;41(3):549–558.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Winter van Rossum I, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5(10):797–807.
   PubMed Web of Science ®Google Scholar
• Meyer J, Stahl S. The Clozapine Handbook. In The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks, pp. I-Ii). Cambridge: Cambridge University Press. 2019.
   Google Scholar
• Farooq S, Choudry A, Cohen D, et al. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsych Bull. 2019;43(1):8–16.
   PubMed Web of Science ®Google Scholar
• Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review. Schizophr Res. 2018;201:10–19.
   PubMed Web of Science ®Google Scholar
• Thien K, O’Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review. Early Interv Psychiatry. 2019;13(1):18–23.
   PubMed Web of Science ®Google Scholar
• Grover S, Hazari N, Chakrabarti S, et al. Delay in initiation of clozapine: a retrospective study from a tertiary care hospital in North India. Psychiatry Res. 2015;226(1):181–185.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Barone A, Vellucci L, et al. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review. Mol Neurobiol. 2022 Oct;59(10):6460–6501.
   PubMed Web of Science ®Google Scholar
• Takaki M, Kodama M, Mizuki Y, et al. Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine. Eur Neuropsychopharmacol. 2018;28(5):610–619.
   PubMed Web of Science ®Google Scholar
• Schrader JM, Irving CM, Octeau JC, et al., The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface. J Biol Chem. 2019;294(14): 5604–5615. .
   PubMed Web of Science ®Google Scholar
• Wagner E, Kane JM, Correll CU, et al. Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working group. Schizophr Bull. 2020;46(6):1459–1470.
   PubMed Web of Science ®Google Scholar
• Joo SW, Kim H, Jo YT, et al. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study. Eur Neuropsychopharmacol. 2022;59:36–44.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatry. 2021;11(8):429–448.
   PubMed Web of Science ®Google Scholar
• Corripio I, Roldán A, Sarró S, et al. Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. EBioMedicine. 2020;51:102568.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Kulsa MKC, Sultana T, et al. Transcranial direct-current stimulation in ultra-treatment-resistant schizophrenia. Brain Stimul. 2019;12(1):54–61.
   PubMed Web of Science ®Google Scholar
• Wagner E, Honer WG, Sommer IE, et al. Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. World J Biol Psychiatry. 2021;22(1):14–26.
   PubMed Web of Science ®Google Scholar
• Maley CT, Becker JE, Shultz EKB. Electroconvulsive therapy and other neuromodulation techniques for the treatment of psychosis. Child Adolesc Psychiatr Clin N Am. 2019;28(1):91–100.
   PubMed Web of Science ®Google Scholar
• Sinclair DJ, Zhao S, Qi F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2019;3(3):Cd011847.
   PubMedGoogle Scholar
• Lally J, Tully J, Robertson D, et al. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2016;171(1–3):215–224.
   PubMed Web of Science ®Google Scholar
• Siskind DJ, Lee M, Ravindran A, et al. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52(8):751–767.
   PubMed Web of Science ®Google Scholar
• Wagner E, Löhrs L, Siskind D, et al. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol. 2019;33(4):423–435.
   PubMed Web of Science ®Google Scholar
• Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res. 2001;48(1):155–158.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1–3):90–94.
   PubMed Web of Science ®Google Scholar
• Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354(5):472–482.
   PubMed Web of Science ®Google Scholar
• Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand. 2004;110(4):292–298.
   PubMed Web of Science ®Google Scholar
• Assion HJ, Reinbold H, Lemanski S, et al., Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41(1): 24–28. .
   PubMed Web of Science ®Google Scholar
• Barnes TR, Leeson VC, Paton C, et al. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2017;21(49):1–56.
   PubMed Web of Science ®Google Scholar
• Mukherjee H, Sazhin V. Predictors of functioning and clinical outcomes in inpatient with schizophrenia on clozapine augmented with antipsychotics. Aus Psychiatry. 2022;30(1):100–104.
   PubMed Web of Science ®Google Scholar
• Bioque M, Parellada E, García-Rizo C, et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Eur Psychiatry. 2020;63(1):e71.
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. 2011;25(5):667–674.
   PubMed Web of Science ®Google Scholar
• Vayısoğlu S, Anıl Yağcıoğlu AE, Yağcıoğlu S, et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res. 2013;143(1):207–214.
   PubMed Web of Science ®Google Scholar
• Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res. 2007;93(1–3):109–116.
   PubMed Web of Science ®Google Scholar
• Bruno A, Zoccali R, Bellinghieri PM, et al. Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. J Clin Psychopharmacol. 2014;34(5):620–623.
   PubMed Web of Science ®Google Scholar
• Leising J, Barr AM, Procyshyn RM, et al. High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis. J Clin Psychopharmacol. 2021;41(2):186–190.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Vellucci L, Austin MC, et al., Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics. Biomolecules. 2022;12(7):909. .
   PubMed Web of Science ®Google Scholar
• Lin CH, Lin CH, Chang YC, et al. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biol Psychiatry. 2018;84(6):422–432.
   PubMed Web of Science ®Google Scholar
• Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488–501.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Barone A, Begni V, et al. Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective. Pharmacol Res. 2022;176:106078.
   PubMed Web of Science ®Google Scholar
• Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.
   PubMed Web of Science ®Google Scholar
• Gründer G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S21–5.
   PubMedGoogle Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100.
   PubMed Web of Science ®Google Scholar
• Amada N, Akazawa H, Ohgi Y, et al. Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5-HT(2A) receptors in rats. Neuropsychopharmacol Rep. 2019;39(4):279–288.
   PubMedGoogle Scholar
• Okada T, Kumakura J, Yasuda M, et al. Treatment-resistant schizophrenia successfully maintained with brexpiprazole following abrupt withdrawal of clozapine due to neutropenia. Asian J Psychiatr. 2020;47:101836.
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Suttajit S, Maneeton N, et al. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res. 2015;62:38–47.
   PubMed Web of Science ®Google Scholar
• Barbui C, Accordini S, Nosè M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol. 2011;31(3):266–273.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Accordini S, Nosè M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol. 2013;33(4):533–537.
   PubMed Web of Science ®Google Scholar
• Viegas F, Ferreira T, Campos C. Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone - Clinical Cases. Neuropsychiatr Dis Treat. 2022;18:1145–1149.
   PubMed Web of Science ®Google Scholar
• Berardis D, Rapini G, Olivieri L, et al. Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clin Psychopharmacol Neurosci. 2021;19(1):174–178.
   PubMed Web of Science ®Google Scholar
• Bogren M, Soltesz M, Hjorth S. Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder. Front Psychiatry. 2022;13:887547.
   PubMed Web of Science ®Google Scholar
• Oloyede E, Clark I, Mace S, et al. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Ther Adv Psychopharmacol. 2022;12:20451253211066642.
   Web of Science ®Google Scholar
• Weise J, Schomerus G, Speerforck S. Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome. Clin Psychopharmacol Neurosci. 2022;20(2):398–401.
   PubMed Web of Science ®Google Scholar
• Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Drugs. 2021;81(11):1273–1284.
   PubMed Web of Science ®Google Scholar
• Azorin JM, Simon N. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opin Drug Metab Toxicol. 2020;16(12):1175–1186.
   PubMed Web of Science ®Google Scholar
• Balcioglu YH, Gokcay H, Yesilkaya UH. One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia. Clin Neuropharmacol. 2020;43(5):166–168.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
   PubMed Web of Science ®Google Scholar
• Karuna Therapeutics K. A study to assess efficacy and safety of adjunctive KarXT in subjects with inadequately controlled symptoms of schizophrenia (ARISE). ClinicalTrials.gov Identifier: NCT05145413.
   Google Scholar
• Karuna Therapeutics K. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia. ClinicalTrials.gov Identifier: NCT05304767 (2022).
   Google Scholar
• ACADIA Pharmaceuticals Inc. Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1). ClinicalTrials.gov Identifier: NCT02970292 (2016).
   Google Scholar
• ACADIA Pharmaceuticals Inc. Extension study of pimavanserin for the adjunctive treatment of schizophrenia. ClinicalTrials.gov Identifier: NCT03121586 (2017).
   Google Scholar
• SyneuRx International. Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults. ClinicalTrials.gov Identifier: NCT02261519 (2014).
   Google Scholar
• SyneuRx International Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®. ClinicalTrials.gov Identifier: NCT01908192. (2013).
   Google Scholar
• Goh KK, Wu TH, Chen CH, et al. Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials. J Psychopharmacol. 2021;35(3):236–252.
   PubMed Web of Science ®Google Scholar
• Alberati D, Moreau JL, Lengyel J, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152–1161.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Nolan KA, Epstein ML, et al. Neurophysiological Effects of Bitopertin in Schizophrenia. J Clin Psychopharmacol. 2017;37(4):447–451.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Podhorna J, Gröschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191–201.
   PubMed Web of Science ®Google Scholar
• Brannan SK, Sawchak S, Miller AC, et al., Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med. 2021;384(8): 717–726.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Breier A, Kavanagh S, et al. Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study. J Clin Psychiatry. 2022;83(3). DOI:10.4088/JCP.21m14316.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Meltzer HA, Dgetluck N, et al. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacol. 2015;40(13):3053–3060.
   PubMed Web of Science ®Google Scholar
• Rowe AR, Mercer L, Casetti V, et al. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol. 2015;29(2):197–211.
   PubMed Web of Science ®Google Scholar
• Money TT, Scarr E, Udawela M, et al. Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord Drug Targets. 2010;9(2):241–256.
   PubMed Web of Science ®Google Scholar
• Brannan S. 32.2 Two global phase iii trials of encenicline for cognitive impairment in chronic schizophrenia patients: red flags and lessons learnED. Schizophr Bull. 2019;45(Supplement_2):S141–S142.
   Google Scholar
• H. Lundbeck A/S. Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (DayBreak). ClinicalTrials.gov Identifier: NCT02717195. 2016.
   Google Scholar
• H. Lundbeck A/S. Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (Anew). 2017.
   Google Scholar
• China Medical University Hospital. DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia. ClinicalTrials.gov Identifier: NCT02532686. (2015).
   Google Scholar
• Neill JC, Barnes S, Cook S, et al., Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128(3): 419–432.
   PubMed Web of Science ®Google Scholar
• Correll CU, Davis RE, Weingart M, et al. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA psychiatry. 2020;77(4):349–358.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952–961.
   PubMed Web of Science ®Google Scholar
• Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016;16(6):601–614.
   PubMed Web of Science ®Google Scholar
• Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl). 2015;232(3):605–621.
   PubMed Web of Science ®Google Scholar
• Greenwood J, Acharya RB, Marcellus V, et al. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother. 2021;55(1):98–104.
   PubMed Web of Science ®Google Scholar
• Lobo MC, Whitehurst TS, Kaar SJ, et al. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324–361.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar i or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098–1106.
   PubMed Web of Science ®Google Scholar
• Blair HA. Lumateperone: First Approval. Drugs. 2020;80(4):417–423.
   PubMed Web of Science ®Google Scholar
• Farah A. High-dose lumateperone: A case report [Letter to the editor Brief article]. Curr Psychiatry. 2021;20:42. .
   Google Scholar
• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA psychiatry. 2020;77(2):201–210.
   PubMed Web of Science ®Google Scholar
• Watson J, Brough S, Coldwell MC, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1998;125(7):1413–1420.
   PubMed Web of Science ®Google Scholar
• Zavitsanou K, Katsifis A, Mattner F, et al. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacol. 2004;29(3):619–625.
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033–1039.
   PubMed Web of Science ®Google Scholar
• Maehara S, Hikichi H, Ohta H. Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice-Possible involvement of muscarinic receptors. Brain Res. 2011;1418:111–119.
   PubMed Web of Science ®Google Scholar
• Xin R, Chen Z, Fu J, et al. Xanomeline Protects Cortical Cells From Oxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis. Front Physiol. 2020;11:656.
   PubMed Web of Science ®Google Scholar
• Anderson P. Positive Phase 3 Results for Novel Schizophrenia Drug 2022 [cited 2022 August 9]. Available from: https://www.medscape.com/viewarticle/978964
   Google Scholar
• Karuna Therapeutics K. A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) - NCT04659161. 2022.
   Google Scholar
• Fellner C. New Schizophrenia Treatments Address Unmet Clinical Needs. P T. 2017;42(2):130–134.
   PubMedGoogle Scholar
• Lundbeck A/S H. Positron Emission Tomography (PET) study investigating dopamine and serotonin receptor occupancy after multiple oral dosing of Lu AF35700 - NCT02333487. 2020
   Google Scholar
• Ľupták M, Michaličková D, Fišar Z, et al. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatry. 2021;11(7):277–296.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Tampi RR, Balaram K, et al. Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review. World J Psychiatry. 2020;10(7):162–174.
   PubMed Web of Science ®Google Scholar
• Bugarski-Kirola D, Arango C, Fava M, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9(1):46–58.
   PubMed Web of Science ®Google Scholar
• ACADIA Pharmaceuticals Inc. Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) - NCT04531982. (2022).
   Google Scholar
• Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1572–1586.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Rizvi S. Augmentation With Pimavanserin in Treatment Refractory Schizophrenia: Case Report. J Clin Psychopharmacol. 2021;41(3):337–339.
   PubMed Web of Science ®Google Scholar
• Schwartz MD, Canales JJ, Zucchi R, et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018;22(6):513–526.
   PubMed Web of Science ®Google Scholar
• Rutigliano G, Accorroni A, Zucchi R. The Case for TAAR1 as a Modulator of Central Nervous System Function. Front Pharmacol. 2017;8:987.
   PubMed Web of Science ®Google Scholar
• Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69.
   PubMedGoogle Scholar
• Revel FG, Moreau JL, Pouzet B, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013;18(5):543–556.
   PubMed Web of Science ®Google Scholar
• Sunovion. A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging - NCT04038957. (2022).
   Google Scholar
• Sunovion. A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia - NCT02969382. 2021.
   Google Scholar
• Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–1506.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Ogirala A, Worden M, et al. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021;41(12):1067–1073.
   PubMed Web of Science ®Google Scholar
• Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol Ther. 2020;205:107426.
   PubMed Web of Science ®Google Scholar
• Lane HY, Lin CH, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA psychiatry. 2013;70(12):1267–1275.
   PubMed Web of Science ®Google Scholar
• Molla G. Competitive Inhibitors Unveil Structure/Function Relationships in Human D-Amino Acid Oxidase. Front Mol Biosci. 2017;4:80.
   PubMed Web of Science ®Google Scholar
• SyneuRx International. An Adaptive Phase II/III,Two-Part, Double-Blind, Randomized, Placebo-controlled,Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults - NCT03094429. 2021.
   Google Scholar
• Harmeier A, Obermueller S, Meyer CA, et al. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015 Nov;25(11):2049–2061. doi: 10.1016/j.euroneuro.2015.08.011. Epub 2015 Aug 20. PMID: 26372541.
   PubMed Web of Science ®Google Scholar
• Jones MT, Strassnig MT, Harvey PD. Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. Expert Opin Emerg Drugs. 2020;25(2):189–200.
   PubMed Web of Science ®Google Scholar
• Scott JG, Baker A, Lim CCW, et al. Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis: A Randomized Clinical Trial. JAMA network open. 2020;3(11):e2024335.
   PubMed Web of Science ®Google Scholar